We showed that the 3-kDa whey ameliorated the PA+HG-related LDH and SREBP1 accrual, as well as PPAR-α and PPAR-γ protein level reduction, suggesting that it could serve as a potential therapeutic strategy in T2DM for targeting PPAR-α and PPAR-γ. Here, SREBF1 is linked to type 2 diabetes mellitus.